Andrew Kennedy

Director, Radiation Oncology Research at Sarah Cannon · SCRI Development Innovations, LLC

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

150

PubMed author-name match

Trials

Studies that name Andrew Kennedy as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov

N/A
NCT05953337 · Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical · active not recruiting · Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer · principal investigator
Ph2
NCT02195011 · Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC · completed · Colorectal Neoplasms · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 150 PubMed records, and a shared surname and initials can bring in a namesake. All 150 on PubMed

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.
Gut · 2005
456 citations
RCR 12.1
The effectiveness and cost effectiveness of a national lay-led self care support programme for patients with long-term conditions: a pragmatic randomised controlled trial.
J Epidemiol Community Health · 2007
233 citations
RCR 8.9
Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease.
Neurosci Lett · 1995
190 citations
RCR 5.2
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.
Lancet Neurol · 2009
189 citations
RCR 4.7
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
Ann Surg · 2008
175 citations
RCR 5.6
Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial.
JAMA · 2002
174 citations
RCR 5.9
Implementation of self management support for long term conditions in routine primary care settings: cluster randomised controlled trial.
BMJ · 2013
170 citations
RCR 8.4
A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease.
Gut · 2004
149 citations
RCR 5.0
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
J Clin Oncol · 2000
141 citations
RCR 3.7
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
J Exp Med · 2016
131 citations
RCR 3.6